Konidaris Tasos 4

4 · Amneal Pharmaceuticals, Inc. · Filed Mar 5, 2026

Insider Transaction Report

Form 4

Period: 2026-03-03

Amneal Pharmaceuticals, Inc.AMRX

Konidaris Tasos

Executive Vice President & CFO

Transactions

Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+45,290→ 167,442 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−16,182$215,382→ 151,260 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+57,339→ 208,599 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−24,251$322,781→ 184,348 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-03+28,538→ 212,886 total
Tax Payment
Class A Common Stock
[F3]
2026-03-03$13.31/sh−14,298$190,306→ 198,588 total
Exercise/Conversion
Class A Common Stock
[F4]
2026-03-03+458,716→ 657,304 total
Tax Payment
Class A Common Stock
[F5]
2026-03-03$13.31/sh−229,817$3,058,864→ 427,487 total
Exercise/Conversion
Class A Common Stock
[F1][F2]
2026-03-04+43,982→ 471,469 total
Tax Payment
Class A Common Stock
[F3]
2026-03-04$13.30/sh−22,035$293,066→ 449,434 total
Exercise/Conversion
Restricted Stock Units
[F2][F6]
2026-03-03−45,290→ 0 total
→ Class A Common Stock (45,290 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F7]
2026-03-03−57,339→ 57,340 total
→ Class A Common Stock (57,339 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F8]
2026-03-03−28,538→ 85,617 total
→ Class A Common Stock (28,538 underlying)
Exercise/Conversion
Performance-Based Restricted Stock Units
[F4]
2026-03-03−458,716→ 0 total
→ Class A Common Stock (458,716 underlying)
Exercise/Conversion
Restricted Stock Units
[F2][F9]
2026-03-04−49,982→ 87,963 total
→ Class A Common Stock (49,982 underlying)

Footnotes (9)

[F1]Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
[F2]Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
[F3]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
[F4]Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. On March 3, 2023, the Reporting Person was granted performance-based restricted stock units, scheduled to vest based on the Issuer's Class A Common Stock achieving certain average closing prices per share over a three-year performance period. These units were certified as meeting the performance threshold that resulted in vesting of 200% of the targeted number of restricted stock units and these restricted stock units were deemed earned and vested on March 3, 2026 and settled into shares of Class A Common Stock on a one-for-one basis. Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of these performance-based restricted stock unites. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 5.
[F5]Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of performance-based restricted stock units.
[F6]On March 3, 2022, the reporting person was granted 181,159 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F7]On March 3, 2023, the reporting person was granted 229,358 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F8]On March 3, 2025, the reporting person was granted 114,155 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.
[F9]On March 4, 2024, the reporting person was granted 175,926 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date.

Signature

/s/ Denis Butkovic, Attorney-in-Fact|2026-03-05

Documents

1 file

4
wk-form4_1772746314.xmlPrimary
FORM 4